H. Kim Lyerly

Duke University — United States

Immunology and Microbiology · Life Sciences

80h-index22.3kcitations715works1.72yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Immunotherapy and Immune Responses(259), Cancer Immunotherapy and Biomarkers(161), CAR-T cell therapy research(135), Monoclonal and Polyclonal Antibodies Research(82), Immune Cell Function and Interaction(72)

Publications710 total

CD27 agonism enhances long-lived CD4 T cell vaccine responses critical for antitumor immunity
Science Immunology·2025
Ultrasound-Enhanced Dye Penetration in Agar Gel Phantoms Using a Trocar-Integrated Dual-Aperture Ultrasound Transducer
2025
A Precision Ultrasound-Localized Sonoporation-Equipment (PULSE) Enabling Intratumoral Delivery for Cancer Immunotherapy
2025· 1 citedOpen Access
CoSiDeX: A hyperspectral fluorescent protein resource for highly multiplexed imaging
2025Open Access
Abstract 2197: Uncovering immune evasion in EGFR-mutant and treatment resistant NSCLC: insights from a novel mouse model
Cancer Research·2025
Abstract 2128: Uncovering the multiple therapeutic mechanisms of trastuzumab deruxtecan (T-DXd): effective extracellular payload release and immunomodulatory stimulation
Cancer Research·2025
Abstract 2675: Tumor clones display intrinsic and stable rates of progression and coordination of the tumor microenvironment in association with epithelial mesenchymal plasticity
Cancer Research·2025
Clinical impact of concurrent autologous adoptive T cells immunotherapy in active COVID-19 infected cancer patients for chemotherapy
Infectious Agents and Cancer·2025· 1 citedOpen Access
Effective extracellular payload release and immunomodulatory interactions govern the therapeutic effect of trastuzumab deruxtecan (T-DXd)
Nature Communications·2025· 60 citedOpen Access
Nonlinear progression during the occult transition establishes cancer lethality
Disease Models & Mechanisms·2025· 1 citedOpen Access
Abstract A104: Targeting the CXCR3 axis in HER2+ breast cancer with mRNA Lipid Nanoparticles to enhance anti-tumor immunity
Cancer Immunology Research·2025
Concurrent autologous adoptive T cells immunotherapy in active COVID-19 infected cancer patients for chemotherapy
2024Open Access
Synchronized autologous T-cell immunotherapy with hyperthermia to previously heavy treated advanced renal cell carcinoma
International Journal of Hyperthermia·2024· 1 citedOpen Access
Vaccination Against Androgen Receptor Splice Variants to Immunologically Target Prostate Cancer
Vaccines·2024· 6 citedOpen Access
Abstract A059: Uncovering Bystander Killing Mechanisms of Trastuzumab Deruxtecan (T-DXd): Effective Extracellular Payload Release via Cathepsin L in HER2-low Breast Cancer.
Cancer Immunology Research·2024· 4 cited
Abstract B009: Enhancing Antitumor Immune Responses: Trastuzumab Deruxtecan (T- DXd) Induces Immunogenic Cell Death and Phagocytosis, Synergizing with CD47/SIRPα Checkpoint Blockade
Cancer Immunology Research·2024· 1 cited
A new model to enhance enrollment of diverse participants to therapeutic clinical trials.
Journal of Clinical Oncology·2024
Abstract PO3-26-06: A self-replicating RNA Precision Immunotherapeutic for Overcoming Resistance to Endocrine Therapy in Estrogen Receptor Positive Breast Cancer (ER+BC)
Cancer Research·2024
Nonlinear progression during the occult transition establishes cancer lethality
2024· 2 citedOpen Access
Table S2 from Overcoming Xenoantigen Immunity to Enable Cellular Tracking and Gene Regulation with Immune-competent “NoGlow” Mice
2024Open Access
page 1 of 36Next →

Frequent Co-authors

Michael A. Morse(18), Timothy M. Clay(13), Takuya Osada(11), Amy Hobeika(10), Smita K. Nair(9), Eli Gilboa(6), A J Langlois(5), David Boczkowski(4), Donna Niedzwiecki(4), Thomas J. Matthews(4), Amy P. Abernethy(4), Paul J. Mosca(4), R. Ian Cumming(3), Julia Kravchenko(3), Neil L. Spector(3), Yuping Deng(3), Jeffrey Schlom(3), David S. Hsu(3), Zachary C. Hartman(3), Kent J. Weinhold(3)